Skip to main content
NCBI home page
Gut logoLink to Gut
. 1997 Apr;40(4):443–448. doi: 10.1136/gut.40.4.443

Tumour necrosis factor and Crohn's disease.

S J Van Deventer 1
PMCID: PMC1027115  PMID: 9176068

Full text

PDF
444

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Albrecht H., Schook L. B., Jongeneel C. V. Nuclear migration of NF-kappa B correlates with TNF-alpha mRNA accumulation. J Inflamm. 1995;45(1):64–71. [PubMed] [Google Scholar]
  2. Amiri P., Locksley R. M., Parslow T. G., Sadick M., Rector E., Ritter D., McKerrow J. H. Tumour necrosis factor alpha restores granulomas and induces parasite egg-laying in schistosome-infected SCID mice. Nature. 1992 Apr 16;356(6370):604–607. doi: 10.1038/356604a0. [DOI] [PubMed] [Google Scholar]
  3. Bazzoni F., Beutler B. The tumor necrosis factor ligand and receptor families. N Engl J Med. 1996 Jun 27;334(26):1717–1725. doi: 10.1056/NEJM199606273342607. [DOI] [PubMed] [Google Scholar]
  4. Beutler B., Greenwald D., Hulmes J. D., Chang M., Pan Y. C., Mathison J., Ulevitch R., Cerami A. Identity of tumour necrosis factor and the macrophage-secreted factor cachectin. Nature. 1985 Aug 8;316(6028):552–554. doi: 10.1038/316552a0. [DOI] [PubMed] [Google Scholar]
  5. Beutler B., Mahoney J., Le Trang N., Pekala P., Cerami A. Purification of cachectin, a lipoprotein lipase-suppressing hormone secreted by endotoxin-induced RAW 264.7 cells. J Exp Med. 1985 May 1;161(5):984–995. doi: 10.1084/jem.161.5.984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Beutler B., Van Huffel C. An evolutionary and functional approach to the TNF receptor/ligand family. Ann N Y Acad Sci. 1994 Aug 15;730:118–133. doi: 10.1111/j.1749-6632.1994.tb44244.x. [DOI] [PubMed] [Google Scholar]
  7. Braegger C. P., Nicholls S., Murch S. H., Stephens S., MacDonald T. T. Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet. 1992 Jan 11;339(8785):89–91. doi: 10.1016/0140-6736(92)90999-j. [DOI] [PubMed] [Google Scholar]
  8. Breese E. J., Michie C. A., Nicholls S. W., Murch S. H., Williams C. B., Domizio P., Walker-Smith J. A., MacDonald T. T. Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease. Gastroenterology. 1994 Jun;106(6):1455–1466. doi: 10.1016/0016-5085(94)90398-0. [DOI] [PubMed] [Google Scholar]
  9. Caput D., Beutler B., Hartog K., Thayer R., Brown-Shimer S., Cerami A. Identification of a common nucleotide sequence in the 3'-untranslated region of mRNA molecules specifying inflammatory mediators. Proc Natl Acad Sci U S A. 1986 Mar;83(6):1670–1674. doi: 10.1073/pnas.83.6.1670. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Carlos T. M., Harlan J. M. Leukocyte-endothelial adhesion molecules. Blood. 1994 Oct 1;84(7):2068–2101. [PubMed] [Google Scholar]
  11. Carroll M. C., Katzman P., Alicot E. M., Koller B. H., Geraghty D. E., Orr H. T., Strominger J. L., Spies T. Linkage map of the human major histocompatibility complex including the tumor necrosis factor genes. Proc Natl Acad Sci U S A. 1987 Dec;84(23):8535–8539. doi: 10.1073/pnas.84.23.8535. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Chensue S. W., Warmington K. S., Ruth J. H., Lincoln P., Kunkel S. L. Cytokine function during mycobacterial and schistosomal antigen-induced pulmonary granuloma formation. Local and regional participation of IFN-gamma, IL-10, and TNF. J Immunol. 1995 Jun 1;154(11):5969–5976. [PubMed] [Google Scholar]
  13. Crowe P. D., Walter B. N., Mohler K. M., Otten-Evans C., Black R. A., Ware C. F. A metalloprotease inhibitor blocks shedding of the 80-kD TNF receptor and TNF processing in T lymphocytes. J Exp Med. 1995 Mar 1;181(3):1205–1210. doi: 10.1084/jem.181.3.1205. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Derkx B., Taminiau J., Radema S., Stronkhorst A., Wortel C., Tytgat G., van Deventer S. Tumour-necrosis-factor antibody treatment in Crohn's disease. Lancet. 1993 Jul 17;342(8864):173–174. doi: 10.1016/0140-6736(93)91375-v. [DOI] [PubMed] [Google Scholar]
  15. Elliott M. J., Maini R. N., Feldmann M., Kalden J. R., Antoni C., Smolen J. S., Leeb B., Breedveld F. C., Macfarlane J. D., Bijl H. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet. 1994 Oct 22;344(8930):1105–1110. doi: 10.1016/s0140-6736(94)90628-9. [DOI] [PubMed] [Google Scholar]
  16. Elliott M. J., Maini R. N., Feldmann M., Long-Fox A., Charles P., Bijl H., Woody J. N. Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis. Lancet. 1994 Oct 22;344(8930):1125–1127. doi: 10.1016/s0140-6736(94)90632-7. [DOI] [PubMed] [Google Scholar]
  17. Elson C. O., Sartor R. B., Tennyson G. S., Riddell R. H. Experimental models of inflammatory bowel disease. Gastroenterology. 1995 Oct;109(4):1344–1367. doi: 10.1016/0016-5085(95)90599-5. [DOI] [PubMed] [Google Scholar]
  18. Elson C. O., Sartor R. B., Tennyson G. S., Riddell R. H. Experimental models of inflammatory bowel disease. Gastroenterology. 1995 Oct;109(4):1344–1367. doi: 10.1016/0016-5085(95)90599-5. [DOI] [PubMed] [Google Scholar]
  19. Farrah T., Smith C. A. Emerging cytokine family. Nature. 1992 Jul 2;358(6381):26–26. doi: 10.1038/358026b0. [DOI] [PubMed] [Google Scholar]
  20. Feldmann M., Brennan F. M., Elliott M. J., Williams R. O., Maini R. N. TNF alpha is an effective therapeutic target for rheumatoid arthritis. Ann N Y Acad Sci. 1995 Sep 7;766:272–278. doi: 10.1111/j.1749-6632.1995.tb26675.x. [DOI] [PubMed] [Google Scholar]
  21. Flory C. M., Jones M. L., Miller B. F., Warren J. S. Regulatory roles of tumor necrosis factor-alpha and interleukin-1 beta in monocyte chemoattractant protein-1-mediated pulmonary granuloma formation in the rat. Am J Pathol. 1995 Feb;146(2):450–462. [PMC free article] [PubMed] [Google Scholar]
  22. Flynn J. L., Goldstein M. M., Chan J., Triebold K. J., Pfeffer K., Lowenstein C. J., Schreiber R., Mak T. W., Bloom B. R. Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity. 1995 Jun;2(6):561–572. doi: 10.1016/1074-7613(95)90001-2. [DOI] [PubMed] [Google Scholar]
  23. Gearing A. J., Beckett P., Christodoulou M., Churchill M., Clements J., Davidson A. H., Drummond A. H., Galloway W. A., Gilbert R., Gordon J. L. Processing of tumour necrosis factor-alpha precursor by metalloproteinases. Nature. 1994 Aug 18;370(6490):555–557. doi: 10.1038/370555a0. [DOI] [PubMed] [Google Scholar]
  24. Giroir B. P., Beutler B. Effect of amrinone on tumor necrosis factor production in endotoxic shock. Circ Shock. 1992 Mar;36(3):200–207. [PubMed] [Google Scholar]
  25. Han J., Thompson P., Beutler B. Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at separate points in the signaling pathway. J Exp Med. 1990 Jul 1;172(1):391–394. doi: 10.1084/jem.172.1.391. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Holländer G. A., Simpson S. J., Mizoguchi E., Nichogiannopoulou A., She J., Gutierrez-Ramos J. C., Bhan A. K., Burakoff S. J., Wang B., Terhorst C. Severe colitis in mice with aberrant thymic selection. Immunity. 1995 Jul;3(1):27–38. doi: 10.1016/1074-7613(95)90156-6. [DOI] [PubMed] [Google Scholar]
  27. Jones M. L., Warren J. S. Monocyte chemoattractant protein 1 in a rat model of pulmonary granulomatosis. Lab Invest. 1992 Apr;66(4):498–503. [PubMed] [Google Scholar]
  28. Jongeneel C. V. Regulation of the TNF alpha gene. Prog Clin Biol Res. 1994;388:367–381. [PubMed] [Google Scholar]
  29. Kayagaki N., Kawasaki A., Ebata T., Ohmoto H., Ikeda S., Inoue S., Yoshino K., Okumura K., Yagita H. Metalloproteinase-mediated release of human Fas ligand. J Exp Med. 1995 Dec 1;182(6):1777–1783. doi: 10.1084/jem.182.6.1777. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Kindler V., Sappino A. P., Grau G. E., Piguet P. F., Vassalli P. The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell. 1989 Mar 10;56(5):731–740. doi: 10.1016/0092-8674(89)90676-4. [DOI] [PubMed] [Google Scholar]
  31. Kohno T., Brewer M. T., Baker S. L., Schwartz P. E., King M. W., Hale K. K., Squires C. H., Thompson R. C., Vannice J. L. A second tumor necrosis factor receptor gene product can shed a naturally occurring tumor necrosis factor inhibitor. Proc Natl Acad Sci U S A. 1990 Nov;87(21):8331–8335. doi: 10.1073/pnas.87.21.8331. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Kuijpers T. W., Hakkert B. C., Hart M. H., Roos D. Neutrophil migration across monolayers of cytokine-prestimulated endothelial cells: a role for platelet-activating factor and IL-8. J Cell Biol. 1992 May;117(3):565–572. doi: 10.1083/jcb.117.3.565. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Lammers K. M., Jansen J., Bijlsma P. B., Ceska M., Tytgat G. N., Laboisse C. L., van Deventer S. J. Polarised interleukin 8 secretion by HT 29/19A cells. Gut. 1994 Mar;35(3):338–342. doi: 10.1136/gut.35.3.338. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Lantz M., Gullberg U., Nilsson E., Olsson I. Characterization in vitro of a human tumor necrosis factor-binding protein. A soluble form of a tumor necrosis factor receptor. J Clin Invest. 1990 Nov;86(5):1396–1402. doi: 10.1172/JCI114853. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Leach M. W., Bean A. G., Mauze S., Coffman R. L., Powrie F. Inflammatory bowel disease in C.B-17 scid mice reconstituted with the CD45RBhigh subset of CD4+ T cells. Am J Pathol. 1996 May;148(5):1503–1515. [PMC free article] [PubMed] [Google Scholar]
  36. Mielke M. E., Rosen H., Brocke S., Peters C., Hahn H. Protective immunity and granuloma formation are mediated by two distinct tumor necrosis factor alpha- and gamma interferon-dependent T cell-phagocyte interactions in murine listeriosis: dissociation on the basis of phagocyte adhesion mechanisms. Infect Immun. 1992 May;60(5):1875–1882. doi: 10.1128/iai.60.5.1875-1882.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Mohler K. M., Sleath P. R., Fitzner J. N., Cerretti D. P., Alderson M., Kerwar S. S., Torrance D. S., Otten-Evans C., Greenstreet T., Weerawarna K. Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processing. Nature. 1994 Jul 21;370(6486):218–220. doi: 10.1038/370218a0. [DOI] [PubMed] [Google Scholar]
  38. Mosmann T. R., Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today. 1996 Mar;17(3):138–146. doi: 10.1016/0167-5699(96)80606-2. [DOI] [PubMed] [Google Scholar]
  39. Myatt N., Coghill G., Morrison K., Jones D., Cree I. A. Detection of tumour necrosis factor alpha in sarcoidosis and tuberculosis granulomas using in situ hybridisation. J Clin Pathol. 1994 May;47(5):423–426. doi: 10.1136/jcp.47.5.423. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Nielsen O. H., Brynskov J., Bendtzen K. Circulating and mucosal concentrations of tumour necrosis factor and inhibitor(s) in chronic inflammatory bowel disease. Dan Med Bull. 1993 Apr;40(2):247–249. [PubMed] [Google Scholar]
  41. Old L. J. Tumor necrosis factor (TNF). Science. 1985 Nov 8;230(4726):630–632. doi: 10.1126/science.2413547. [DOI] [PubMed] [Google Scholar]
  42. Paleolog E. M., Delasalle S. A., Buurman W. A., Feldmann M. Functional activities of receptors for tumor necrosis factor-alpha on human vascular endothelial cells. Blood. 1994 Oct 15;84(8):2578–2590. [PubMed] [Google Scholar]
  43. Perez C., Albert I., DeFay K., Zachariades N., Gooding L., Kriegler M. A nonsecretable cell surface mutant of tumor necrosis factor (TNF) kills by cell-to-cell contact. Cell. 1990 Oct 19;63(2):251–258. doi: 10.1016/0092-8674(90)90158-b. [DOI] [PubMed] [Google Scholar]
  44. Powrie F., Correa-Oliveira R., Mauze S., Coffman R. L. Regulatory interactions between CD45RBhigh and CD45RBlow CD4+ T cells are important for the balance between protective and pathogenic cell-mediated immunity. J Exp Med. 1994 Feb 1;179(2):589–600. doi: 10.1084/jem.179.2.589. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Powrie F., Leach M. W., Mauze S., Menon S., Caddle L. B., Coffman R. L. Inhibition of Th1 responses prevents inflammatory bowel disease in scid mice reconstituted with CD45RBhi CD4+ T cells. Immunity. 1994 Oct;1(7):553–562. doi: 10.1016/1074-7613(94)90045-0. [DOI] [PubMed] [Google Scholar]
  46. Reinecker H. C., Steffen M., Witthoeft T., Pflueger I., Schreiber S., MacDermott R. P., Raedler A. Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin Exp Immunol. 1993 Oct;94(1):174–181. doi: 10.1111/j.1365-2249.1993.tb05997.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Sartor R. B. Cytokines in intestinal inflammation: pathophysiological and clinical considerations. Gastroenterology. 1994 Feb;106(2):533–539. doi: 10.1016/0016-5085(94)90614-9. [DOI] [PubMed] [Google Scholar]
  48. Scallon B. J., Moore M. A., Trinh H., Knight D. M., Ghrayeb J. Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine. 1995 Apr;7(3):251–259. doi: 10.1006/cyto.1995.0029. [DOI] [PubMed] [Google Scholar]
  49. Schuerer-Maly C. C., Eckmann L., Kagnoff M. F., Falco M. T., Maly F. E. Colonic epithelial cell lines as a source of interleukin-8: stimulation by inflammatory cytokines and bacterial lipopolysaccharide. Immunology. 1994 Jan;81(1):85–91. [PMC free article] [PubMed] [Google Scholar]
  50. Simpson S. J., Mizoguchi E., Allen D., Bhan A. K., Terhorst C. Evidence that CD4+, but not CD8+ T cells are responsible for murine interleukin-2-deficient colitis. Eur J Immunol. 1995 Sep;25(9):2618–2625. doi: 10.1002/eji.1830250932. [DOI] [PubMed] [Google Scholar]
  51. Strober W., Ehrhardt R. O. Chronic intestinal inflammation: an unexpected outcome in cytokine or T cell receptor mutant mice. Cell. 1993 Oct 22;75(2):203–205. doi: 10.1016/0092-8674(93)80062-j. [DOI] [PubMed] [Google Scholar]
  52. Tartaglia L. A., Goeddel D. V. Two TNF receptors. Immunol Today. 1992 May;13(5):151–153. doi: 10.1016/0167-5699(92)90116-O. [DOI] [PubMed] [Google Scholar]
  53. Tracey K. J., Cerami A. Tumor necrosis factor: a pleiotropic cytokine and therapeutic target. Annu Rev Med. 1994;45:491–503. doi: 10.1146/annurev.med.45.1.491. [DOI] [PubMed] [Google Scholar]
  54. Tsuji M., Dimov V. B., Yoshida T. In vivo expression of monokine and inducible nitric oxide synthase in experimentally induced pulmonary granulomatous inflammation. Evidence for sequential production of interleukin-1, inducible nitric oxide synthase, and tumor necrosis factor. Am J Pathol. 1995 Oct;147(4):1001–1015. [PMC free article] [PubMed] [Google Scholar]
  55. Van Zee K. J., Moldawer L. L., Oldenburg H. S., Thompson W. A., Stackpole S. A., Montegut W. J., Rogy M. A., Meschter C., Gallati H., Schiller C. D. Protection against lethal Escherichia coli bacteremia in baboons (Papio anubis) by pretreatment with a 55-kDa TNF receptor (CD120a)-Ig fusion protein, Ro 45-2081. J Immunol. 1996 Mar 15;156(6):2221–2230. [PubMed] [Google Scholar]
  56. Williams L. M., Gibbons D. L., Gearing A., Maini R. N., Feldmann M., Brennan F. M. Paradoxical effects of a synthetic metalloproteinase inhibitor that blocks both p55 and p75 TNF receptor shedding and TNF alpha processing in RA synovial membrane cell cultures. J Clin Invest. 1996 Jun 15;97(12):2833–2841. doi: 10.1172/JCI118739. [DOI] [PMC free article] [PubMed] [Google Scholar]
  57. Zabel P., Wolter D. T., Schönharting M. M., Schade U. F. Oxpentifylline in endotoxaemia. Lancet. 1989 Dec 23;2(8678-8679):1474–1477. doi: 10.1016/s0140-6736(89)92929-2. [DOI] [PubMed] [Google Scholar]
  58. van der Poll T., Büller H. R., ten Cate H., Wortel C. H., Bauer K. A., van Deventer S. J., Hack C. E., Sauerwein H. P., Rosenberg R. D., ten Cate J. W. Activation of coagulation after administration of tumor necrosis factor to normal subjects. N Engl J Med. 1990 Jun 7;322(23):1622–1627. doi: 10.1056/NEJM199006073222302. [DOI] [PubMed] [Google Scholar]
  59. van der Poll T., Levi M., Büller H. R., van Deventer S. J., de Boer J. P., Hack C. E., ten Cate J. W. Fibrinolytic response to tumor necrosis factor in healthy subjects. J Exp Med. 1991 Sep 1;174(3):729–732. doi: 10.1084/jem.174.3.729. [DOI] [PMC free article] [PubMed] [Google Scholar]
  60. van der Poll T., Levi M., Hack C. E., ten Cate H., van Deventer S. J., Eerenberg A. J., de Groot E. R., Jansen J., Gallati H., Büller H. R. Elimination of interleukin 6 attenuates coagulation activation in experimental endotoxemia in chimpanzees. J Exp Med. 1994 Apr 1;179(4):1253–1259. doi: 10.1084/jem.179.4.1253. [DOI] [PMC free article] [PubMed] [Google Scholar]
  61. van der Poll T., Levi M., van Deventer S. J., ten Cate H., Haagmans B. L., Biemond B. J., Büller H. R., Hack C. E., ten Cate J. W. Differential effects of anti-tumor necrosis factor monoclonal antibodies on systemic inflammatory responses in experimental endotoxemia in chimpanzees. Blood. 1994 Jan 15;83(2):446–451. [PubMed] [Google Scholar]
  62. van der Poll T., van Deventer S. J., Hack C. E., Wolbink G. J., Aarden L. A., Büller H. R., ten Cate J. W. Effects on leukocytes after injection of tumor necrosis factor into healthy humans. Blood. 1992 Feb 1;79(3):693–698. [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES